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Centre for Neuroendocrinology and Department of Anatomy, University of Otago, Dunedin, New ZealandTo most biomedical scientists, the anterior pituitary hormone, tors are also highly expressed in the choroid plexus, a structure found
prolactin, will rightly be thought of as the hormone responsible for
lactation. However, this is just one of this remarkable molecule's func-
tions. Prolactin might better be thought of as a pleiotropic cytokine
with diverse functions in different tissues (Bole-Feysot et al., 1998;
Grattan and LeTissier, 2015). In the May issue of EBioMedicine, Garcia
et al. add a new function to this already long list (Garcia et al., 2016):
an anti-apoptotic protective role maintaining the function of the retinal
pigment epithelium (RPE). While prolactin receptor expression had
previously been identiﬁed in the retina, prolactin's functional role in
the RPE has, until the present study, been poorly understood.
The RPE forms an integral part of the structure and function of the
retina. Apart from absorption of light, it also forms a blood/retinal
ﬂuid barrier to maintain appropriate electrolyte balance in the
subretinal space and to control nutrient supply to photoreceptors. The
RPE plays a critical role in recycling retinal to maintain photoreceptor
excitability (the so-called "visual cycle"), and it secretes a number of
growth factors to help maintain the function of the local tissues,
including the photoreceptor cells (Strauss, 2005). Dysregulation of the
RPE is implicated in a number of retinal diseases, including age-
related decline in visual function. Further understanding of the regula-
tion of RPE function is clearly important for development of therapies
for degenerative diseases of the retina that lead to impaired vision or
even blindness. Hence, the discovery by Garcia et al. of a protective
role of prolactin in the RPE, along with insight into the anti-apoptotic
mechanisms, is signiﬁcant because it may provide opportunities for
developing novel therapeutics targeting this system.
While an effect of this “lactation hormone” on the RPE might seem
surprising, it is perhaps not so dissimilar from other recognised func-
tions of prolactin throughout phylogeny, where regulation of ion trans-
port and secretion from integument and other epithelial cells has been
shown from ﬁsh to birds tomammals (Bole-Feysot et al., 1998). In addi-
tion to integument epithelial tissue, like the mammary gland, prolactin
has actions in a wide range of epithelia, including kidney, intestine and
the prostate gland (Bole-Feysot et al., 1998). Similar to the nervous sys-
tem role now identiﬁed in the RPE (Garcia et al., 2016), prolactin recep-DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.03.048.
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nal ﬂuid (CSF). Here, prolactin seems to act to regulate the composition
of the CSF, perhaps helping to maintain the blood/CSF barrier (Grattan,
2015). The protective function of prolactin seen in the RPE is also consis-
tent with known actions of prolactin in a number of other tissues, rang-
ing from stem cells to the brain, where it promotes cell division and cell
survival. Indeed, growth and survival of rat NB2 lymphoma cells has
long been utilised as a highly sensitive bioassay for prolactin (Lawson
et al., 1982). The anti-apoptotic actions of prolactin are likely to have
important physiological roles, but may also underlie the oncogenic po-
tential of this hormone in mammary, prostate and other cancers
(Gofﬁn and Touraine, 2015).
Using a combination of human and rodent cell lines, as well as
in vivo studies using age-related decline in retinal function in mice
lacking the prolactin receptor gene, Garcia et al. have demonstrated a
protective role for prolactin in RPE homeostasis (Garcia et al., 2016).
They have also demonstrated that this is mediated by suppression of
apoptosis, driven by reduced oxidative stress, consequent inhibition of
expression of sirtuin 2, and reduced signalling through TRPM2 channels.
Thus, they have identiﬁed amechanism thatmight enable development
of novel therapies for retinal disorders. However, a number of questions
remain. Antagonist studies revealed that endogenous prolactin medi-
ates the anti-apoptotic effect, but it is still unclear to what extent this
is through prolactin synthesised locally, within the retina, or pituitary
prolactin arriving via the systemic circulation. While Garcia et al. pres-
ent some data suggestive of limited local synthesis (for example in
RPE cell lines), it is difﬁcult to determinewhat levelsmight be produced
from this source, and it seems highly likely that circulating prolactin
would also contribute to this effect. If this is correct, the obvious ques-
tion is whether there are endogenous adaptive changes in RPE function
during times when circulating prolactin is elevated, such as during
pregnancy or lactation. Another question is the relationship of the pro-
tective function of prolactin with similar actions of the related
vasoinhibin molecules. In previous studies, this group demonstrated
that vasoinhibins protected the retina from diabetic retinopathy
(Arnold et al., 2010). Vasoinhibins are produced as proteolytically-
cleaved fragments of prolactin and act by inhibiting vascular permeabil-
ity, but do not act through the prolactin receptor (Triebel et al., 2015).
Hence, the balance between prolactin and vasoinhibin signalling in a
particular tissue might be critical to the overall outcome. In manythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
27D.R. Grattan / EBioMedicine 8 (2016) 26–27tissues, these two molecules have opposite effects, but in the retina,
both seem to exert protective actions, and the relative contributions of
this combination will be important to understand.
As a potential therapeutic target, the pleiotropic actions of prolactin
engender both excitement and frustration. Excitement, because clear
beneﬁcial actions shown in the lab seem to have huge potential for
developing new treatments. Frustration, because with so many other
tissues possibly inﬂuenced by prolactin, it might be difﬁcult to target ef-
fects speciﬁcally to the tissue of interest (Gofﬁn and Touraine, 2015).
Nevertheless, it seems inevitable that studies such as these are bringing
us closer to harnessing the potential of this multifunctional molecule,
and I look forward with interest to further developments coming from
this group of researchers, and others stimulated by their ﬁndings.
Conﬂicts of interest
The author declares no conﬂicts of interest.
References
Arnold, E., Rivera, J.C., Thebault, S., Moreno-Paramo, D., Quiroz-Mercado, H., Quintanar-
Stephano, A., Binart, N., Martinez de la Escalera, G., Clapp, C., 2010. High levels ofserum prolactin protect against diabetic retinopathy by increasing ocular
vasoinhibins. Diabetes 59, 3192–3197.
Bole-Feysot, C., Gofﬁn, V., Edery, M., Binart, N., Kelly, P.A., 1998. Prolactin (PRL) and its
receptor: actions, signal transduction pathways and phenotypes observed in PRL
receptor knockout mice. Endocr. Rev. 19, 225–268.
Garcia, R.M., Zamarripa, D.A., Arnold, E., Ruiz-Herrera, X., Imm, R.N., Cruz, G.B., Adan,
N., Binart, N., Riesgo-Escovar, J., Gofﬁn, V., et al., 2016. Prolactin protects retinal
pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine
http://dx.doi.org/10.1016/j.ebiom.2016.03.048.
Gofﬁn, V., Touraine, P., 2015. The prolactin receptor as a therapeutic target in human dis-
eases: browsing new potential indications. Expert Opin. Ther. Targets 19, 1229–1244.
Grattan, D.R., 2015. 60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-prolactin
axis. J. Endocrinol. 226, T101–T122.
Grattan, D.R., LeTissier, P., 2015. Hypothalamic Control of Prolactin Secretion, and the
Multiple Reproductive Functions of Prolactin. In: Plant, T.M., Zelesnik, A.J. (Eds.),
Knobil and Neill's Physiology of Reproduction, 4th Ed. Elsevier, pp. 469–526.
Lawson, D.M., Sensui, N., Haisenleder, D.H., Gala, R.R., 1982. Rat lymphoma cell bioassay
for prolactin: observations on its use and comparison with radioimmunoassay. Life
Sci. 31, 3063–3070.
Strauss, O., 2005. The retinal pigment epithelium in visual function. Physiol. Rev. 85,
845–881.
Triebel, J., Bertsch, T., Bollheimer, C., Rios-Barrera, D., Pearce, C.F., Hufner, M., Martinez de
la Escalera, G., Clapp, C., 2015. Principles of the prolactin/vasoinhibin axis. Am. J. Phys.
Regul. Integr. Comp. Phys. 309, R1193–R1203.
